

PATENT
IN UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: 7,531,665

Docket No: 17543CON2 (AP)

Issue Date: May 12, 2009

Patentee: Steven W. Andrews et al.

Title KINASE INHIBITORS FOR THE TREATMENT OF DISEASE

REQUEST FOR CERTIFICATION OF CORRECTION

Attn: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

It is requested that a Certificate of Correction be issued correcting printing errors appearing in the above-identified United States patent. Two copies of the text of the Certificate in the suggested form are enclosed.

Pursuant to 1.20(a), the examiner is authorized to charge the Certificate of Correction fee of \$100.00 to the Deposit Account No.01-0885.

Issuance of the Certificate of Correction would neither expand nor contract the scope of the claims as properly allowed, and re-examination is not required.

The Examiner is authorized to charge any additional fees or credit overpayment to Deposit Account No.01-0885.

Respectfully submitted,

/Joel B. German/

Date: June 10, 2009

By: Joel B. German

Reg. No.: 48,676

Allergan, Inc.
2525 Dupont Drive - T2-7H
Irvine, CA 92612
Telephone: 714-246-4920
Fax: 714-246-4249

Customer Number: 051957

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 7,531,665

Page 1 of 3

APPLICATION NO.: 10/829,139

ISSUE DATE : May 12, 2009

INVENTOR(S) : Steven W. Andrews et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Face Page, under "Other Publications", column 2, line 24, delete ""Inibition" and insert -- "Inhibition --, therefor.

In column 1, line 39, delete "extracellular" and insert -- extracellular --, therefor.

In column 2, line 27, delete "(FLK4)" and insert -- (FLK-4) --, therefor.

In column 3, line 11, delete "cyclopropyl4" and insert -- cyclopropyl-4 --, therefor.

In column 3, line 16, delete "seleioindoles" and insert -- selenoindoles --, therefor.

In column 3, line 45, delete "Devisiion)," and insert -- Division), --, therefor.

In column 5, line 36, delete "C₁," and insert -- C₁ --, therefor.

In column 5, line 38, delete "C₁," and insert -- C₁ --, therefor.

In column 6, line 6, delete "dioxoiane," and insert -- dioxolane, --, therefor.

In column 6, line 25-26, delete "morpholonyl;" and insert -- morpholinyl; --, therefor.

In column 7, line 43, delete "piperzinyll," and insert -- piperazinyll, --, therefor.

In column 7, line 67, before "R^{2a}" delete "with".

In column 8, line 13-14, delete "(CR^aR^b)_dR," and insert -- (CR^aR^b)_dR⁷, --, therefor.

In column 9, line 36, delete "alkyaryl," and insert -- alkylaryl, --, therefor.

MAILING ADDRESS OF SENDER:

PATENT NO. 7,531,665

Joel B. German-T2-7H
Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612

No. of additional copies



Atty Docket No: 17543CON2 (AP)

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

PATENT NO : 7,531,665

Page 2 of 3

APPLICATION NO.: 10/829,139

ISSUE DATE : May 12, 2009

INVENTOR(S) : Steven W. Andrews et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 10, line 46, delete "Examples15" and insert -- Examples 15 --, therefor.

In column 11, line 53, delete "Ca⁺⁺Signal" and insert -- Ca⁺⁺ Signal --, therefor.

In column 12, line 45, delete "isofluorane," and insert -- isoflurane, --, therefor.

In column 12, line 48-49, delete "isofluorane," and insert -- isoflurane, --, therefor.

In column 13, line 17, delete "bums" and insert -- burns --, therefor.

In column 14, line 48, delete "Morpoholin" and insert -- Morpholin --, therefor.

In column 14, line 53, delete "μL" and insert -- mL --, therefor.

In column 14, line 59, delete "μL" and insert -- mL --, therefor.

MAILING ADDRESS OF SENDER:

PATENT NO. 7,531,665

Joel B. German-T2-7H
Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612

No. of additional copies



Atty Docket No: 17543CON2 (AP)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 7,531,665

Page 3 of 3

APPLICATION NO.: 10/829,139

ISSUE DATE : May 12, 2009

INVENTOR(S) : Steven W. Andrews et al.

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 17, line 38, delete "Morpholin4" and insert - - Morpholin-4 - -, therefor.

In column 21, line 4, in Claim 1, delete "atom" and insert - - atom, - -, therefor.

In column 21, line 42, in Claim 2, delete "1 -(2-methoxyethyl)" and insert - - 1-(2-methoxyethyl) - -, therefor.

In column 22, line 10, in Claim 2, delete "histamyl ," and insert - - histamyl, - -, therefor.

MAILING ADDRESS OF SENDER:

Joel B. German-T2-7H
Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612

PATENT NO. 7,531,665

No. of additional copies



Atty Docket No: 17543CON2 (AP)